HALO
Halozyme Therapeutics Inc
113.90$
-1.1%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +79.3% | +8.6% | +115.8% | -52.0% | +29.1% | +36.5% | +65.7% | +48.9% | +25.6% | +22.4% | +37.6% | |
| – | +28.7% | +13.5% | -6.2% | -67.5% | +349.3% | -4.8% | +87.7% | +71.1% | +38.1% | -17.1% | +91.6% | |
| – | +101.2% | +7.3% | +151.5% | -50.4% | +6.2% | +49.0% | +61.4% | +43.9% | +22.3% | +34.4% | +27.5% | |
| – | +17.0% | +61.8% | -0.1% | -0.3% | -6.3% | -75.7% | +4.2% | +86.7% | +14.6% | +3.5% | +3.1% | |
| – | +11.4% | +14.6% | +17.4% | +13.0% | +27.1% | -40.8% | +10.0% | +185.2% | +3.9% | +3.5% | +34.2% | |
| – | +15.2% | +47.6% | +3.9% | +3.2% | +3.3% | -63.3% | +7.5% | +194.5% | +18.2% | +1.7% | -9.7% | |
| – | – | – | – | -185.6% | – | – | +91.3% | -3.0% | +26.2% | +63.4% | +48.0% | |
| – | -6.8% | +284.1% | +10.0% | -17.9% | -35.6% | +75.3% | -63.1% | +125.2% | +10.7% | -3.6% | +0.2% | |
| – | – | – | – | -229.5% | – | – | +92.2% | +0.2% | +39.9% | +59.9% | -16.2% | |
| – | -7.7% | -67.0% | -217.1% | – | -102.0% | – | -71,156.2% | – | +42.6% | +69.4% | +32.7% | |
| – | – | – | – | -227.6% | – | – | +212.0% | -49.8% | +39.3% | +57.7% | -28.6% | |
| – | – | – | – | -180.5% | – | – | +89.0% | +13.1% | +43.2% | +45.3% | -12.7% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.